

1 **Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus**  
2 **Disease 2019 (COVID-19): A Single-center, Open label, Randomised**  
3 **Controlled Trial**

4 Authors:

5 Jia Liu<sup>b,1</sup>, Wei Yang<sup>b,1</sup>, Yue Liu<sup>c,1</sup>, Cheng Lv<sup>b,1</sup>, Lianguo Ruan<sup>d,1</sup>, Chen Zhao<sup>b,1</sup>, Ruili  
6 Huo<sup>a,1</sup>, Xin Shen<sup>e,1</sup>, Qing Miao<sup>c,1</sup>, Wenliang Lv<sup>f,1</sup>, Hao Li<sup>c,1</sup>, Huaxin Shi<sup>a,1</sup>, Lijie Hu<sup>a,1</sup>,  
7 Zhixu Yang<sup>c,1</sup>, Li Zhang<sup>c,1</sup>, Bing Wang<sup>c,1</sup>, Guoju Dong<sup>c,1</sup>, Yongyue Xian<sup>c,1</sup>, Bin Li<sup>c,1</sup>,  
8 Zhenqi Zhou<sup>c,1</sup>, Chunyan Xu<sup>c,1</sup>, Yingying Chen<sup>c,1</sup>, Yongjun Bian<sup>f,1</sup>, Jing Guo<sup>f,1</sup>, Jinliang  
9 Yang<sup>f,1</sup>, Jian Wang<sup>f,1</sup>, Wensheng Qi<sup>f,1</sup>, Suping Chen<sup>f,1</sup>, Yang Chen<sup>f,1</sup>, Bei Yan<sup>f,1</sup>, Wei  
10 Wang<sup>f,1</sup>, Jing Li<sup>c,1</sup>, Xiaolei Xie<sup>c,1</sup>, Ming Xu<sup>c,1</sup>, Jianxin Jiang<sup>c,1</sup>, Gang Wang<sup>c,1</sup>, Xiaodong  
11 Cong<sup>c,1</sup>, Haoning Zhu<sup>c,1</sup>, Jiaheng Shi<sup>f,1</sup>, Luxing Leng<sup>f,1</sup>, Dongxu Li<sup>f,1</sup>, Lanping Guo<sup>g,1</sup>, Luqi

12 Huang<sup>\*a,h,1</sup>

- 13 a. China Academy of Chinese Medical Sciences, Beijing, China  
14 b. China Academy of Chinese Medical Sciences Institute of Basic research in Clinical  
15 Medicine, Beijing, China  
16 c. China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China  
17 d. Wuhan Jinyintan Hospital, Wuhan, Hubei, China  
18 e. China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica,  
19 Beijing, China  
20 f. China Academy of Chinese Medical Sciences Guanganmen Hospital, Beijing, China  
21 g. China Academy of Chinese Medical Sciences Chinese Materia Medica Resource  
22 Center, Beijing, China  
23 h. China Center for Evidence-based Medicine of Traditional Chinese Medicine, China  
24 Academy of Chinese Medical Sciences, Beijing, China

25 \*Corresponding author:

26 Luqi Huang, Professor, China Center for Evidence-based Medicine of Traditional  
27 Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China

28 [Tel: +86 64089838](tel:+8664089838); [fax: +86 64089838](tel:+8664089838)

29 E-mail: [huanglq@cacms.cn](mailto:huanglq@cacms.cn)

30 <sup>1</sup>The authors contributed to this work equally;

31

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71

## ABSTRACT

### *OBJECTIVE*

To evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care compared with standard care alone in adult with coronavirus disease 2019 (COVID-19).

### *Study DESIGN*

Single-center, open label, randomised controlled trial.

### *SETTING*

Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.

### *PARTICIPANTS*

204 patients with laboratory confirmed COVID-19 were randomised in to treatment group and control group, which was 102 patients each group.

### *INTERVENTIONS*

In treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days and plus standard care. In control group, patients were given standard care alone for 14 days.

### *MAIN OUTCOME MEASURE*

The primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events were analyzed in the safety population.

### *RESULTS*

Among 204 patients, 195 were analyzed according to the intention to treat principle. There were 149 patients (71 vs. 78 in treatment group and control group respectively) turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in conversion time between treatment group and control group (FAS: Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.). Time to recovery of fever was shorter in treatment group as compared in control group. The disappearance rate of symptom in cough, fatigue, chest discomfort was significantly higher in treatment group. In chest computed tomography (Chest CT) examinations, overall evaluation of chest CT examination after treatment compared with baseline showed more patients improved in treatment group .There were no significant differences in the other outcomes.

### *CONCLUSION*

Administration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported.

### *TRIAL REGISTRATION*

ChiCTR2000030288

72

73 *Keywords*

74 COVID-19; Chinese medicine; efficacy; safety; Randomised Controlled Trial; Q-14

75

76 **Abbreviations:** CI, Confidence interval; CNMTCM-CACMS, China National Medical  
77 Team of Traditional Chinese Medicine of China Academy of Chinese Medical Sciences;  
78 CONSORT, Consolidated Standards of Reporting Trials; COVID-19, Coronavirus Disease  
79 2019; CT, Computed tomography; ECMO, Extracorporeal membrane oxygenation; FAS,  
80 Full Analysis Set; GCP, Good Clinical Practice; IQR, Interquartile range;  
81 NHC-NATCM-China guidelines, National clinical practice guideline for COVID-19 in  
82 China” developed by the National Health Commission and the National  
83 Administration of TCM of the People’s Republic of China; PPS, Per-protocol Set;  
84 RT-PCR, Reverse-transcription polymerase chain reaction; SCIO-China, State Council  
85 Information Office of the People's Republic of China; TCM, Traditional Chinese  
86 medicine; WHO, World Health Organization

87

88

## 89 INTRODUCTION

90 CoronaVirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has resulted  
91 in considerable morbidity and mortality in more than 200 countries, which has  
92 become a major public health crisis on a global scale (Wang et al., 2020). By August  
93 24, 2020, the number of confirmed cases of COVID-19 has reached more than 23  
94 million, the total reported deaths now exceeds 800,000 globally, with rapid daily  
95 increases in some countries (WHO, 2020). Information regarding the epidemiology  
96 and clinical features of COVID-19 (Wu et al., 2020; Chen et al., 2020) provides good  
97 support for its clinical prevention and treatment, but many of the drugs previously  
98 hailed as star drugs, such as remdesivir, favipiravir, lopinavir-ritonavir and  
99 chloroquine or hydroxychloroquine have not shown ideal results in clinical trials,  
100 even some of them has been found to have obvious toxic side effects (Wang et al.,  
101 2020; Tang et al. 2020). Scientists around the world are actively seeking potential  
102 effective drugs or developing vaccine to treat COVID-19.

103

104 China quickly halted the spread of COVID-19 with strong containment measures (Li et  
105 al., 2020). The strategy of integrated traditional Chinese medicine (TCM) with  
106 western medicine plays an important role in the prevention and control of COVID-19  
107 in China, more than 90% confirmed cases have received TCM therapy (SCIO-China,  
108 2020). At the beginning of COVID-19, China National Medical Team of Traditional  
109 Chinese Medicine of China Academy of Chinese Medical Sciences (CNMTCM-CACMS  
110 Team) went to Wuhan to carry out integrated TCM with Western medicine treatment  
111 for COVID-19 in Wuhan Jinyintan Hospital, which is one of the hospitals receiving  
112 most of COVID-19 patients. In the absence of specific drugs for an emerging  
113 infectious disease, based on the theory of TCM with thousands of years of experience  
114 in the prevention and treatment of infectious disease, in particular, accumulated  
115 clinical experience of TCM in the SARS in 2003, Chinese medicine (Q-14) was  
116 developed to clinical application for treatment of COVID-19 in Wuhan, China. Q-14,  
117 also known as *Huashi Baidu granule*, is a compound granules composed of 14

118 Chinese herbs (see supplementary data). The National Health Commission and the  
119 National Administration of TCM of the People's Republic of China developed  
120 "National clinical practice guideline for COVID-19 in China" (NHC-NATCM-China  
121 guidelines) ([NHC-China, 2020](#)), Q-14 is one of the main Chinese herbal preparations  
122 for the treatment of COVID-19 in NHC-NATCM-China guidelines, which was widely  
123 used in clinical practice during the outbreak of COVID-19 in Wuhan, China. One of the  
124 important ways to improve the international recognition of Chinese herbal medicine  
125 is to evaluate the clinical efficacy and safety of Chinese herbal medicine with  
126 evidence-based medicine ([Tang, 2006](#)).

127

128 At the critical moment of the COVID-19 outbreak in Wuhan of China, we conducted a  
129 single-center, open label, randomised controlled trial to assess the efficacy and safety  
130 of Q-14 in hospitalized adults with laboratory-confirmed COVID-19.

131

132

## 133 **METHODS**

### 134 ***Trial Oversight***

135 In this open-label randomised trial, we recruited patients with COVID-19 from Wuhan  
136 Jinyintan Hospital, Wuhan, China. The protocol was designed in compliance with the  
137 Declaration of Helsinki, Good Clinical Practice guidelines, and local regulatory  
138 requirements. The study protocol had been approved by the Ethics Review  
139 Committee of China Academy of Chinese Medical Sciences. The protocol has been  
140 registered in China Clinical Trial Registry website ([www.chictr.org/cn/](http://www.chictr.org/cn/),  
141 ChiCTR2000030288). All patients had given written informed consent.

142

143 China Academy of Chinese Medical Sciences research group provided the Chinese  
144 Medicine composition and Guangdong Yifang Pharmaceutical Co.,Ltd produced the  
145 compound granules. The results of this trial are reported in accordance with  
146 CONSORT (Consolidated Standards of Reporting Trials) guidelines.

147

148 ***Trial design, randomization, and procedures***

149 This study was a single-center, randomised, parallel, open label trial of Q-14 in  
150 patients with laboratory confirmed COVID-19. Participants were enrolled by  
151 investigators working in Wuhan Jinyintan Hospital. No placebo was used, and  
152 compound granules were not masked. SAS 9.4 software was used to generate  
153 random sequences in a 1:1 ratio by an independent statistician from China Center for  
154 Evidence-Based Traditional Chinese Medicine who was not aware of the trial protocol.  
155 Two research nurses, used a mobile software program “CLINICALCRS” to apply for  
156 randomization number and assigned participants to interventions. All patients  
157 accepted standard care in accordance with the NHC-NATCM-China guidelines  
158 (version 6.0, published on February 18, 2020). Patients in treatment group were  
159 given Q-14 the day after randomization, with a dose of 10g (granules), twice daily for  
160 14 days continuously. The day of randomization was defined as day 0 and the  
161 following days were defined as day 1 to day 14. Investigators, patients and  
162 statisticians were not masked to group assignment. The routine care and laboratory  
163 staff were unaware of the treatment. Research data was recorded using Medroad  
164 Cloud Electronic Data Capture System (Jiangsu Famous Medicine  
165 Science and Technology Ltd.) Double data entry was carried out by two different  
166 recorder. Study quality control was executed in three levels, including first level by  
167 clinical research associate, second level by independent GCP (Good Clinical Practice)  
168 staffs who did not participate in the trial, third level by clinical research management  
169 department of China Academy of Chinese Medical Sciences.

170

171 ***Patients***

172 We recruited 204 patients with laboratory confirmed COVID-19 in Wuhan Jinyintan  
173 Hospital during February 27 to March 27, 2020.

174

175 The inclusion criteria included: 1) Comply with the diagnostic criteria for general type  
176 COVID-19 in the NHC-NATCM-China guidelines (version 6.0); 2)  $18 \leq \text{Aged} \leq 75$  years; 3)  
177 Agree to participate in the trial, and the patient, the legal guardian or the person in

178 charge of the medical institution signed the informed consent through paper  
179 signature.

180

181 The exclusion criteria included: 1) Critical patients; 2) Patients who cannot guarantee  
182 compliance of using Q-14 during the treatment period, or patients who are difficult  
183 to take medicine by oral or nasal route; 3) Patients with severe primary respiratory  
184 disease or other pathogenic microbial pneumonia that needs to be identified with  
185 COVID-19; 4) Pregnant or parturient women including patient who have a pregnancy  
186 plan or a positive urine pregnancy test; 5) Patients with other systemic malignant  
187 diseases such as malignant tumors, mental illnesses, etc., which the researchers  
188 consider unsuitable for participation in the trial; 6) Patients who have been allergic or  
189 intolerant to taking Chinese medicine herb.

190

191 The definition of critical patients was in accordance with the disease severity of  
192 COVID-19 in “National clinical practice guideline for COVID-19 in China (version 6.0).

193

#### 194 ***Outcome and Assessment***

195 The primary outcome in this trial was conversion time of SARS-CoV-2 viral assay. The  
196 secondary outcomes were: 1) The change of 7-point scale; 2) The rate of critical  
197 aggravation; 3) Blood routine test outcomes; 4) Blood biochemical test outcomes; 5)  
198 Fever recovery time; 6) Symptom improvement; 7) Evaluation of chest CT  
199 examination after treatment compared with baseline. Adverse events were reviewed  
200 daily to assure the safety of patients.

201

202 SARS-CoV-2 viral assay for specimens from upper respiratory tract were tested on day  
203 0, and day 7 to 15. If the test result was negative, SARS-CoV-2 viral assay would be  
204 conducted at least 24 hours later to observe whether there were two consecutive  
205 reports of negative result. When there were two consecutive negative results, the  
206 patient was defined to a conversion-of-negative ending and the day of the first  
207 negative report was determined as the conversion day. The time from day 0 to

208 conversion day was defined as the conversion time.

209

210 The 7-point scale was a seven-category ordinal scale to test the condition and  
211 prognosis of severity during treatment. It consisted of the following categories: 1,  
212 not hospitalized with resumption of normal activities; 2, not hospitalized, but unable  
213 to resume normal activities; 3, hospitalized, not requiring supplemental oxygen;  
214 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal  
215 high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized,  
216 requiring ECMO (extracorporeal membrane oxygenation), invasive mechanical  
217 ventilation, or both; and 7, death. The 7-point scale was recorded during days 1 to day  
218 14. The change of 7-point scale was the score difference after treatment when  
219 comparing with baseline.

220

221 The classification of COVID-19 was recorded on day 0, 1 to 14. The classification  
222 included four categories, mild, moderate, severe and critical with the sequence of  
223 severity increasing. If the classification changed to critical during days 1 to 14, the  
224 patient would be defined as critical aggravation. The rate of critical aggravation  
225 patient would be counted after treatment.

226

227 Blood routine test and blood biochemical test outcomes included complete blood cell  
228 count with differential, blood chemistry, C-reactive protein, hypersensitive C-reactive  
229 protein, amyloid protein, myohemoglobin, hypersensitive troponin,  
230 erythrocyte sedimentation rate, ferroprotein, D-Dimer, interleukin 6, were tested on  
231 day 0, 7, 14.

232

233 Vital signs were recorded on day 0, 1 to 14. If body temperature had a fever, which  
234 was defined as over 37.3°C, we recorded the day when it began to keep stable below  
235 37.3°C to determine fever recovery time.

236

237 The symptom including cough, fatigue, headache, chest discomfort and sore throat  
238 was recorded on day 0 and 14. The disappearance of symptom will be recorded after  
239 treatment. The symptom improvement was evaluated by the disappearance rate of  
240 the five symptoms.

241

242 Chest computed tomography examinations were tested on day 0, 14. Two radiologists  
243 with at least 20 years working experience reviewed the CT reports and images, who  
244 was unaware of the randomization. The judgment of chest CT including: 1) Score of  
245 ground glass area; 2) Score of consolidation area; 3) Density change of ground glass  
246 imaging manifestation; 4) Density change of consolidation imaging manifestation; 5)  
247 Overall evaluation of chest CT examination after treatment compared with baseline.  
248 To count the score of lesion area, each lung was divided into 10 regions according to  
249 anatomy, which were 20 regions for both sides. If the lesion area was over 50%  
250 (contained) in one region, it would be judged as 2 point, and if below 50%, it would  
251 be judged as 1 point. The range of scores for area was 0 to 40 points. Density change  
252 was recorded after treatment as decreased, no-change or increased. Overall  
253 evaluation of chest CT examination was the case and proportion of improved,  
254 no-change, and aggravated patients in each group.

255

256 In this trial, we recorded the timing, duration, severity, management and  
257 consequence of adverse events, and determined the association with the usage of  
258 study medications. (Annex 1)

259

### 260 ***Statistical analysis***

261 The sample size was calculated based on the alternative hypothesis that the hazard  
262 ratio of SARS-CoV-2 viral assay negative conversion rate between treatment group  
263 and control group during the 14-day trial period was  $\theta \neq 1$ . It was assumed that the  
264 SARS-CoV-2 viral assay negative conversion time followed an exponential distribution.  
265 We assumed that the SARS-CoV-2 viral assay negative conversion rate was 0.6 in all

266 patients within 14 days, and the hazard ratio  $\theta=2$  based on the experience of  
267 treatment at the time. The sample size distribution between treatment group and  
268 control group was 1:1, the one-side superiority type I error was 0.05, and the type II  
269 error was 0.2, that is, the power was 80%. We estimated a total sample size of 204 at  
270 the drop-out rate of 15%.

271

272 For primary outcome, the SARS-CoV-2 viral assay negative conversion time, we firstly  
273 used Wilcoxon rank sum test to test the difference of SARS-CoV-2 viral assay negative  
274 conversion time between treatment group and control group, and gave the medians  
275 and IQR (interquartile range). Then, kaplan-Meier method was used to estimate the  
276 cumulative negative conversion rate and draw the survival curve, and the negative  
277 conversion rate was compared among groups through log-rank test, the median time  
278 and 95% CIs (confidence interval) were given, and the hazard ratios was estimated by  
279 Cox regression model. Hazard ratios greater than 1 indicated that the negative  
280 conversion rate of treatment group was higher than that of control group.

281

282 For secondary outcomes, the change of 7-point scale was tested by Wilcoxon rank  
283 sum test. The rate of critical aggravation was tested by Pearson chi-square test. Both  
284 blood routine and blood biochemistry outcomes were numerical data, which was  
285 tested by t-test for normal distribution data and Wilcoxon rank sum test for  
286 non-normal distribution data. Fever recovery time was tested by Wilcoxon rank sum  
287 test. For symptom improvements, which meant the disappearance rate of cough,  
288 chest tightness, headache, fatigue, and pharynx, we used the Pearson chi-square test.  
289 For the chest CT outcome, the score of area and density for both ground glass and  
290 consolidation imaging manifestation, and overall evaluation of chest CT examination,  
291 were tested by Wilcoxon rank sum test.

292

293 Safety analyses were based on the patients' actual exposure to treatment. In this  
294 study, statistical packages base, Stats, Rcompanion and survival in R version-3.6.2 and

295 SPSS 20.0 were used for statistical analysis and verification.

296

### 297 ***Patient and public involvement***

298 No patients were involved in the research design and implementation plan. There is  
299 no plan to disseminate the result of this trial to study participants.

300

301

## 302 **RESULT**

### 303 ***Patients***

304 Of the 285 patients were assessed from February 27 to March 27, 81 did not meet  
305 the eligibility criteria. Remaining 204 patients were randomised with a ratio 1:1 to  
306 treatment group and control group. 195 patients were included in the FAS (Full  
307 Analysis Set) (99 in treatment group and 96 in control group) (**Figure 1**).The mean age  
308 was 54 years old, and 36.4% was male. **Table 1** showed baseline demographic, clinical  
309 characteristics of patients in treatment group and control group.

310

### 311 ***Primary outcome***

312 Among 195 patients in FAS, 149 (76.4%) patients (71 treatment group, 78 control  
313 group) had converted to negative before the cut-off day of analysis, and the  
314 remaining 46 patients (28 treatment group, 18 control group) did not arrive a  
315 conversion-to-negative result.

316

317 In the conversion time of SARS-CoV-2 viral assay, there was no significant difference  
318 between treatment group and control group both in FAS and PPS (Per-protocol Set)  
319 (FAS: n=149. Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank:  
320 67.92 vs. 81.44; P=0.051. PPS: n=148. Median (IQR): 10.00 (9.00, 11.00) vs. 10.00  
321 (9.00, 11.00); Mean rank: 67.86 vs. 80.46; P=0.068). The average time of conversion-  
322 to-negative showed some advantage in treatment group (Mean (SD): FAS: 10.01 (1.74)  
323 vs. 10.44(1.49) days. PPS: 10.04 (1.73) vs. 10.44(1.49) days).The median time to

324 conversion between treatment group and control group showed no significant  
325 difference as well (FAS: 10.00 (9.00-10.00) vs. 10.00 (10.00-11.00) days, HR: 1.165,  
326 95%CI: 0.84-1.61, P=0.27. PPS: 10.00 (9.00-11.00) vs. 10.00 (10.00-11.00) days, HR =  
327 1.15, 95%CI: 0.83-1.59, P=0.31 by log rank test. **Figure 2, Figure 3**).

328

329 We found among the 116 participants with cardiovascular disease who reached  
330 conversion-to-negative, the conversion time of SARS-CoV-2 viral assay is significantly  
331 shorter in treatment group as compared with control group.(Median (IQR): 10.00  
332 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 51.63 vs. 65.61; P=0.022.). The  
333 average time of conversion- to-negative showed some advantage in treatment group  
334 (Mean (SD): FAS: 9.85 (1.42) vs. 10.54 (1.56) days). The median time to conversion  
335 between treatment group and control group showed significantly difference (10.00  
336 (9.00-10.00) vs. 10.00 (10.00-11.00) days, HR: 1.484, 95%CI: 1.02-2.15, P=0.023 by  
337 log rank test. **Figure 4**).

338

### 339 **Secondary outcome**

340 The change of the 7-point scale was similar in the two groups (Median (ICQ): FAS:  
341 -2.00(-3.00-0.00) vs. -2.00(-3.00-0.00), P=0.109. PPS: -2.00(-3.00, 0.00) vs. -2.00(-3.00,  
342 0.00), P=0.232).

343

344 There was no patient turned critical category during the observation.

345

346 There was no significant difference in blood routine test and blood biochemical test.

347

348 Fever recovery time was shorter in treatment group as compared in control group  
349 (Median (ICQ): FAS: 2.00 (2.00-3.00) vs. 3.00 (1.00-4.00) days, P=0.029. PPS: 2.00  
350 (2.00-3.00) vs. 3.00 (1.00-4.00), P=0.049).

351

352 The symptom disappearance rate of cough (FAS: 90.7% vs. 79.5%, P=0.045. PPS:  
353 91.7% vs. 79.5%, P=0.028), fatigue (FAS: 88.1% vs. 75.9%, P=0.038. PPS: 87.8% vs.

354 75.9%, P=0.045), chest discomfort (FAS: 87.0% vs. 67.8%, P=0.015. PPS: 88.5% vs.  
355 67.8%, P=0.009) was significant higher in treatment group. The symptom  
356 disappearance rate of headache (FAS and PPS: 85.7% vs. 83.3%, P> 0.999) and sore  
357 throat (FAS: 82.8% vs. 74.7%, P=0.195. PPS: 81.7% vs. 74.7%, P=0.272) was similar in  
358 the two groups.

359 In chest computed tomography (Chest CT) examinations, the score of ground glass  
360 area was significantly lower in treatment group than control group after  
361 treatment(Median (ICQ):FAS: 8.50 (5.00-15.25) vs. 14.00 (7.00-21.75) , P=0.031. PPS:  
362 9.00 (4.62-16.00) vs. 14.00 (7.00-21.75), P=0.042)with a larger decrease (Median  
363 (ICQ):FAS: -5.75 (-11.25- -2.00) vs.-0.75 (-2.12-2.12), P< 0.001. PPS: -6.50 (-11.75-  
364 -2.00) vs.-0.75 (-2.12-2.12), P< 0.001). The density of ground glass area showed a  
365 significant decrease in treatment group (FAS: decreased 36 (80.0%), no-change  
366 9(20.0%), increased 0 (0%) vs. decreased 17 (51.5%), no-change 15(45.5%), increased  
367 1(3.0%), P=0.007.PPS: decreased 33 (78.6%), no-change 9(21.4%), increased 0 (0%) vs.  
368 decreased 17 (51.5%), no-change 15(45.5%), increased 1(3.0%), P=0.013.)Overall  
369 evaluation of chest CT examination after treatment compared with baseline showed  
370 more patients improved in treatment group (FAS: improved69 (85.2%), no-change  
371 12(14.8%), aggravated 0 (0%) vs. improved55 (67.9%), no-change 23(28.4%),  
372 aggravated 1(3.7%), P=0.008.PPS: improved65 (85.5%), no-change 11(14.5%),  
373 aggravated 0 (0%) vs. improved 55 (67.9%), no-change 23(28.4%), aggravated 1(3.7%),  
374 P=0.008.)There was no significant difference in score of area and density of  
375 consolidation manifestation.

376

### 377 **Safety**

378 Among 204 patients, a total of 202 cases were analyzed as the safety population (100  
379 treatment group, 102 control groups), as there were two patients who were assigned  
380 to treatment group withdraw their informed consent on the day of randomization  
381 and having no baseline information. The comparison of recorded adverse events  
382 showed there were 14 patients (16 adverse events) in treatment group and 15  
383 patients (23 adverse events)) in control group (Table 2). There were no serious

384 adverse events recorded. Diarrhea (n=15) was the most common adverse event in  
385 this trial. For patients who happened digestive discomfort, the Q-14 dosage in  
386 treatment group adjusted to half dosage daily until the symptom improved. Other  
387 adverse events were transient with duration of one to two days.

388

389

## 390 **DISCUSSION**

391 This clinical trial (conducted during the outbreak of COVID-19 in Wuhan, China) is the  
392 first registered randomised controlled trial evaluating administration of Q-14 in  
393 hospitalized adult patients with laboratory confirmed COVID-19 in Wuhan, China.  
394 These finds provide evidence to support a notable improvement of typical  
395 uncomfortable symptoms caused by COVID-19, such as fever, cough, fatigue and  
396 chest discomfort. Additional, a significant improvement of Chest CT by a 14-day  
397 course of Q-14 administration to the standard care in hospitalized adult patients with  
398 COVID-19.

399

400 At present, there is no definite antiviral drug to accelerate the probability of  
401 negativeconversion for SARS-CoV-2 ([Parvathaneni and Gupta, 2020](#); [Yadav et al, 2020](#)),  
402 the development of a vaccine ([Torreele, 2020](#); [Wang et al., 2020](#)) appears to be the  
403 last straw for prevention and control of COVID-19. The development of new antiviral  
404 requires a considerable length of time and effort for drug design and validation.  
405 Clearly, not only will this take time, but everything is unknown. Administration of  
406 Q-14 did not resultin a significantly higher probability of negativeconversion than  
407 standard of care alone in patientsadmitted to hospital with COVID-19, but it is  
408 beneficial for the improvement of typical symptoms in COVID-19 patients.  
409 Improvement in clinical symptoms is important to reduce the level of discomfort in  
410 hospitalized adult patients with COVID-19, at the same time; it is beneficial to relieve  
411 depressive or anxiety caused by typical symptoms of COVID-19 patients or medical  
412 workers ([Elhadi et al., 2020](#); [Wang et al., 2020](#)), such as fever, cough, fatigue and

413 chest discomfort. In our study, the safety of Q-14 has been fully investigated. No  
414 serious adverse events were reported except for diarrhea (8 cases of treatment group)  
415 or other adverse reactions in some patients, which resolve themselves within a few  
416 days. The overall clinical safety of a 14-day course of Q-14 administration is  
417 documented.

418

419 On the other hand, we performed a subgroup analysis, an increase the probability of  
420 negative conversion of SARS-CoV-2 viral assay conferred by the addition of a 14-day  
421 course of Q-14 administration to the standard care in hospitalized adult patients with  
422 COVID-19 and cardiovascular diseases. Although the results were statistically  
423 significant, they were not particularly significant in terms of time (days). This is not  
424 within our expectation, which is an interesting finding. Although we cannot rule out  
425 the possibility of a chance finding, we think it may be related to the following factor.  
426 The majority of COVID-19 patients with cardiovascular diseases are hypertensive;  
427 Q-14 may have a certain targeted improvement effect on the pathological status of  
428 hypertension addition of standard care. Molecular docking showed that baicalein and  
429 quercetin were the top two compounds of Q14, baicalein had strong affinity for  
430 SARS-CoV-2, and quercetin had strong affinity for ACE2 3CL that indicated that  
431 baicalein and quercetin might play an important role in the treatment of SARS-CoV-2  
432 ([Tao et al., 2020](#)). Future clinical studies with a larger sample are needed to confirm  
433 this effect of Q-14. COVID-19 patients with pre-existing cardiovascular diseases  
434 experience disproportionately worse outcomes in mortality ([Peng et al., 2020](#);  
435 [Golemi et al., 2020](#)), the findings of this clinical study may provide an effective drug  
436 for the prevention and treatment of COVID-19 patients with hypertension. Of course,  
437 more rigorous clinical and basic research is needed to validate the speculation.

438

439 Chest CT is used for diagnosis of COVID-19, as an important complement to the  
440 RT-PCR (reverse-transcription polymerase chain reaction) tests ([Ai et al., 2020](#); [Wong  
441 et al., 2020](#)). In the early stages of the COVID-19 epidemic, chest CT may be of  
442 greater diagnostic value than RT-PCR tests. At the same time, it will be a very

443 important observational indicator to evaluate the curative effect for therapeutic  
444 schedule. Not only that, scientists have proposed a non-invasive and quantitative  
445 prognostic tool for predicting poor outcome in patients with COVID-19 based on CT  
446 imaging (Wu et al.,2020). Our study found that after 14 days of treatment, Q-14 with  
447 standard care can significantly improve abnormal chest CT changes of COVID-19  
448 patients, decreased the score of ground glass area (characteristic chest CT change of  
449 COVID-19) significantly. This result suggests that Q-14 has an important therapeutic  
450 role in alleviating the condition of COVID-19 patients.

451

452 More and more clinical evidence shows the great role of TCM in the prevention and  
453 control of COVID-19 (Hu et al., 2020; Xiao et al., 2020; Xiong et al., 2020). From these  
454 studies, we have not seen that Traditional Chinese medicine has a direct antiviral  
455 effect in clinical practice, but its ability to quickly relieve clinical symptoms may be  
456 closely related to the enhancement of the immune ability of the body.

457

#### 458 **LIMITATIONS OF STUDY**

459 Some limitations existed in the present study. First, we did not set up a placebo as a  
460 Q-14 control. In the context of the COVID-19 early outbreak in Wuhan, China, many  
461 clinical trials related COVID-19 has yet to be better prepared because of Wuhan  
462 quarantine, especially for Q-14 placebo. As we did not adopt stratify randomisation  
463 according to disease severity, the cases of severe patient showed significant  
464 difference between the two groups. This may have greatly influenced the conclusions  
465 of this trial, placebo effect of Q-14 cannot be ruled out. Secondly, the open label  
466 rather than double blind design, which may be resulted in possibility of biased  
467 assessments. Thirdly, we began to determine SARS-CoV-2 RNA conversion from the  
468 7th day of the intervention, which may have overlooked some patients who have  
469 negative conversion of SARS-CoV-2 within 7 days. Finally, the specimens collected in  
470 our trial for SARS-CoV-2 RNA determination were mostly from the upper respiratory  
471 tract rather than bronchoalveolar lavage fluid, which could result in false negative

472 results.

473

## 474 **CONCLUSION AND POLICY IMPLICATIONS**

475 The introduction of TCM into the world is a demand of The Times, which is the  
476 worldwide urgent demand for TCM. This trial provides evidence to support a notable  
477 improvement of typical uncomfortable symptoms caused by COVID-19, such as fever,  
478 cough, fatigue and chest discomfort. Additional, a significant improvement of Chest  
479 CT by the addition of a 14-day course of Q-14 administration to the standard care in  
480 hospitalized adult patients with COVID-19. In the current situation, Q-14 may provide  
481 safe and effective option for controlling the spread of COVID-19, or a solution with  
482 Chinese characteristics. China's great success in prevention and control of COVID-19  
483 has demonstrated the feasibility of Chinese Approach.

484

## 485 **FUNDING**

486 The study was funded by National Key Research and Development Plan for the  
487 Emergency Management of Novel Coronavirus Pneumonia (No. 2020YFC0841500)

488

## 489 **AUTHOR'S CONTRIBUTION**

490 JL,WY contributed equally to this paper and share joint first authorship. JL  
491 contributed to the writing on this paper and in charge of the trial management  
492 during this study. WY contributed to the data cleaning and statistical analysis. YL  
493 contributed to the result analysis and modified the study report. CL contributed to  
494 the data collection organization on-site in Wuhan Jinyint Hospital and carried out the  
495 first level quality control. LR contributed to the organization in Wuhan Jinyintan  
496 Hospital and communicated with the patients. CZ designed the protocol and finished  
497 the trial registration. RH contributed to the data cleaning and assisted the trial  
498 management. XS led the data collection and data recording. QM, WL, HL contributed  
499 as clinical expert on-site in Wuhan Jinyintan Hospital from protocol designing to  
500 implementation. HS contributed to the trial drug coordinating on-site in Wuhan.

501 YC,ZZ contributed to randomisation number application. LH, ZY, LZ, BW, GD, YX, BL,  
502 CX, YC, YB, JG, JY, JW, WQ, SC, BY, WW, JL, XX, MX, JJ, GW, XC contributed to  
503 the implementation of intervention during this trial.HZ, JS, LL, DL contributed to  
504 collect data on-site in Wuhan. LG contributed to finalize the structure of this paper.  
505 LH organized the research group and contributed to the overall designing and  
506 management of this trial for the corresponding authorship.

## 507 **ACKNOWLEDGEMENTS**

508 We thank China National Medical Team of Traditional Chinese Medicine of China  
509 Academy of Chinese Medical Sciences (CNMTCM-CACMS Team), who went to Wuhan  
510 in the most critical moment for medical aid and with their hard working, we finished  
511 this trial. The member of CNMTCM-CACMS Team including Luqi Huang, Cheng Lv,  
512 Qing Miao, Wenliang Lv, Hao Li, Huaxin Shi, Lijie Hu, Zhixu Yang, Li Zhang, Bing Wang,  
513 Guoju Dong, Yongyue Xian, Bin Li, Zhenqi Zhou, Chunyan Xu, Yingying Chen, Yongjun  
514 Bian, Jing Guo, Jinliang Yang, Jian Wang, Wensheng Qi, Suping Chen, Yang Chen, Bei  
515 Yan, Wei Wang, Jing Li, Xiaolei Xie, Ming Xu, Jianxin Jiang, Gang Wang, Xiaodong Cong,  
516 Haoning Zhu, Jiaheng Shi, Luxing Leng, Dongxu Li. Xinghua Xiang and Yunfei Xing  
517 assisted the statistical work. Mingjiang Yao, Ping He, Xiao Liang, Ruiyan Cao, Li Li,  
518 Benliang Zou, Ning Wang, Shihuan Tang, Min Li, Xunlu Yin, Hao Wang, Chuanzhou  
519 Yang, Chunyu Gao, Liying Wang, Yongli Dong, Ming Chen, Lu Zhang, Xu Wei  
520 contributed to the data recording. Yang Zhao, Qiaoning Yang, Rui Li, Yingjue Jia, Yu  
521 Dong carried out the second level quality control. Hongjun Yang carried out the third  
522 level quality control and Yanping Wang contributed to the management of the trial.  
523 Xuedong Yang and Chunzhi Li contributed to the CT reports and images review. Meng  
524 Wu contributed to the CT review data verifying.

## 525 **DECLARATION OF COMPETING INTEREST**

526 None.

## 527 **EXCLUSIVE LICENCE**

528 The Corresponding Author has the right to grant on behalf of all authors and does  
529 grant on behalf of all authors, a worldwide licence to the Publishers and its licensees

530 in perpetuity, in all forms, formats and media according to the requirement on  
531 exclusive licence of the publication.

532 **DATA AVAILABILITY STATEMENT**

533 The data of this article could be shared within six months after the trial complete via  
534 the Medroad Cloud Electronic Data Capture System (<http://cloud.medroad.cn/>).

535

## 536 References

- 537 Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L.,2020. Correlation of Chest CT and  
538 RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014  
539 Cases. *Radiology* 296, E32-E40. <http://doi: 10.1148/radiol.2020200642>.
- 540 Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J,  
541 Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q., 2020. Clinical characteristics of 113  
542 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 368, m1091.  
543 <https://doi: 10.1136/bmj.m1091>
- 544 Elhadi M, Msherghi A, Elgzairi M, Alhashimi A, Bouhuwaish A, Biala M, Abuelmeda S, Khel S, Khaled  
545 A, Alsoufi A, Elmabrouk A, Alshiteewi FB, Alhadi B, Alhaddad S, Gaffaz R, Elmabrouk O, Hamed T.B.,  
546 Alameen H, Zaid A, Elhadi A, Albakoush A., 2020. Psychological status of healthcare workers  
547 during the civil war and COVID-19 pandemic: A cross-sectional study. *J Psychosom Res* 137,  
548 110221. <http://doi: 10.1016/j.jpsychores.2020.110221>.
- 549 Golemi Minga I, Golemi L, Tafur A, Pursnani A., 2020. The Novel Coronavirus Disease (COVID-19)  
550 and Its Impact on Cardiovascular Disease. *Cardiol Rev* 28, 163-176. [http://doi:](http://doi: 10.1097/CRD.0000000000000317)  
551 [10.1097/CRD.0000000000000317](http://doi: 10.1097/CRD.0000000000000317).
- 552 Hu K, Guan W.J., Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J,  
553 Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS., 2020. Efficacy and safety of Lianhuaqingwen  
554 capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter,  
555 prospective, randomized controlled trial. *Phytomedicine* ,153242. [http://doi:](http://doi: 10.1016/j.phymed.2020.153242)  
556 [10.1016/j.phymed.2020.153242](http://doi: 10.1016/j.phymed.2020.153242).
- 557 Li Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, Zhang R, An Z, Yin W, Chen W, Qin Y, Peng Z, Zhang T,  
558 Ni D, Cui J, Wang Q, Yang X, Zhang M, Ren X, Wu D, Sun X, Li Y, Zhou L, Qi X, Song T, Gao GF, Feng  
559 Z; China CDC COVID-19 Emergency Response Strategy Team., 2020. Active case finding with case  
560 management: the key to tackling the COVID-19 pandemic. *Lancet* 396, 63-70. [https://doi:](https://doi: 10.1016/S0140-6736(20)31278-2)  
561 [10.1016/S0140-6736\(20\)31278-2](https://doi: 10.1016/S0140-6736(20)31278-2).
- 562 National Health Commission of the People's Republic of China (NHC-China) and National  
563 Administration of Traditional Chinese Medicine of the People's Republic of China, published on  
564 February 18, 2020. National clinical practice guideline for COVID-19 in China (Tentative 6th  
565 edition). February 19, 2020.  
566 [http://www.gov.cn/zhengce/zhengceku/2020-02/19/content\\_5480948.htm](http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm)
- 567 Parvathaneni V, Gupta V., 2020. Utilizing drug repurposing against COVID-19 - Efficacy, limitations,  
568 and challenges. *Life Sci* 259, 118275. <http://doi: 10.1016/j.lfs.2020.118275>.
- 569 Peng Y, Meng K, He M, Zhu R, Guan H, Ke Z, Leng L, Wang X, Liu B, Hu C, Ji Q, Keerman M, Cheng L,  
570 Wu T, Huang K, Zeng Q., 2020. Clinical Characteristics and Prognosis of 244 Cardiovascular  
571 Patients Suffering from Coronavirus Disease in Wuhan, China. *J Am Heart Assoc* 9, e016796.  
572 <http://doi: 10.1161/JAHA.120.016796>.
- 573 Tang J, 2006. Research priorities in traditional Chinese medicine. *BMJ* 333, 391-394. [http://doi:](http://doi: 10.1136/bmj.333.7564.391)  
574 [10.1136/bmj.333.7564.391](http://doi: 10.1136/bmj.333.7564.391).
- 575 Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J,  
576 Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. 2020. Hydroxychloroquine  
577 in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised  
578 controlled trial. *BMJ* 369, m1849. <https://doi: 10.1136/bmj.m1849>

- 579 Tao Q, Du J, Li X, Zeng J, Tan B, Xu J, Lin W, Chen X.L., 2020. Network pharmacology and molecular  
580 docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment  
581 of COVID-19. *Drug Dev Ind Pharm* 46, 1345-1353. [http://doi: 10.1080/03639045.2020.1788070](http://doi:10.1080/03639045.2020.1788070).
- 582 The State Council Information Office of the People's Republic of China. Fighting Covid-19: China in  
583 Action. June 7, 2020. <http://www.scio.gov.cn/zfbps/32832/Document/1681809/1681809.htm>
- 584 Torreele E, 2020. The rush to create a covid-19 vaccine may do more harm than good. *BMJ* 370,  
585 m3209. [http://doi: 10.1136/bmj.m3209](http://doi:10.1136/bmj.m3209).
- 586 Wang C, Horby P.W., Hayden F.G., Gao G.F., 2020. A novel coronavirus outbreak of global health  
587 concern. *Lancet* 395, 470-473. [https://doi: 10.1016/S0140-6736\(20\)30185-9](https://doi:10.1016/S0140-6736(20)30185-9).
- 588 Wang E.A., Zenilman J, Brinkley-Rubinstein L, 2020. Ethical Considerations for COVID-19 Vaccine  
589 Trials in Correctional Facilities. *JAMA* 324, 1031-1032. [http://doi: 10.1001/jama.2020.15589](http://doi:10.1001/jama.2020.15589).
- 590 Wang W, Song W, Xia Z, He Y, Tang L, Hou J, Lei S., 2020. Sleep Disturbance and Psychological  
591 Profiles of Medical Staff and Non-Medical Staff during the Early Outbreak of COVID-19 in Hubei  
592 Province, China. *Front Psychiatry* 11, 733. [http://doi: 10.3389/fpsyt.2020.00733](http://doi:10.3389/fpsyt.2020.00733).
- 593 Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li  
594 H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W,  
595 Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki  
596 T, Hayden FG, Horby PW, Cao B, Wang C., 2020. Remdesivir in adults with severe COVID-19: a  
597 randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 395, 1569-1578.  
598 [https://doi: 10.1016/S0140-6736\(20\)31022-9](https://doi:10.1016/S0140-6736(20)31022-9).
- 599 World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) Weekly Epidemiological  
600 Update. August 24, 2020.  
601 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200824-weekly-epi-up>  
602 [date.pdf?sfvrsn=806986d1\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200824-weekly-epi-update.pdf?sfvrsn=806986d1_2)
- 603 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S,  
604 Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y., 2020.  
605 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With  
606 Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 180, 934-943.  
607 [https://doi: 10.1001/jamainternmed.2020.0994](https://doi:10.1001/jamainternmed.2020.0994)
- 608 Wong H.Y.F., Lam H.Y.S., Fong A.H., Leung S.T., Chin T.W., Lo C.S.Y., Lui M.M., Lee J.C.Y., Chiu K.W.,  
609 Chung T.W., Lee E.Y.P., Wan E.Y.F., Hung I.F.N., Lam T.P.W., Kuo M.D., Ng M.Y., 2020. Frequency and  
610 Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology* 296,  
611 E72-E78. [http://doi: 10.1148/radiol.2020201160](http://doi:10.1148/radiol.2020201160).
- 612 Wu Q, Wang S, Li L, Wu Q, Qian W, Hu Y, Li L, Zhou X, Ma H, Li H, Wang M, Qiu X, Zha Y, Tian J., 2020.  
613 Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19.  
614 *Theranostics* 10, 7231-7244. [http://doi: 10.7150/thno.46428](http://doi:10.7150/thno.46428).
- 615 Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, Peng M, Zhang Y, Yan D, Lang S, Zhang Q, Fan A, Ke J, Li X,  
616 Liu B, Jiang M, Liu Q, Zhu J, Yang L, Zhu Z, Zeng K, Li C, Zheng Y, Wu H, Lin J, Lian F, Li X, Tong  
617 X., 2020. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment  
618 of COVID-19: A randomized controlled trial. *Pharmacol Res* 161,105126. [http://doi: 10.1016/j.phrs.2020.105126](http://doi:10.1016/j.phrs.2020.105126).
- 620 Xiong X, Wang P, Su K, Cho W.C., Xing Y., 2020. Chinese herbal medicine for coronavirus disease  
621 2019: A systematic review and meta-analysis. *Pharmacol Res* 160,105056. [http://doi: 10.1016/j.phrs.2020.105056](http://doi:10.1016/j.phrs.2020.105056).
- 622

623 Yadav M, Dhagat S, Eswari J.S., 2020. Emerging strategies on in silico drug development against  
624 COVID-19: challenges and opportunities. Eur J Pharm Sci 155, 105522. [http://doi:](http://doi:10.1016/j.ejps.2020.105522)  
625 [10.1016/j.ejps.2020.105522](http://doi:10.1016/j.ejps.2020.105522).  
626

627 **Figure legend**

628 Figure 1. Research flow chart

629 Figure 2. Time to conversion analysis of SARS-CoV-2 viral assay and  
630 conversion ending (n=149, FAS)

631 Figure 3. Time to conversion analysis of SARS-CoV-2 viral assay and  
632 conversion ending (n=148, PPS)

633 Figure 4. Time to conversion analysis of SARS-CoV-2 viral assay and  
634 conversion ending, in participants with cardiovascular disease who  
635 reached negative conversion (n=116)

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664





Figure 1. Research flow chart



665


666

667

**Figure 2. Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending (n=149, FAS)**

668

669




670

671

**Figure 3. Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending (n=148, PPS)**

672

673



674

675

676

677

678

**Figure 4. Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending, in participants with cardiovascular disease who reached negative conversion (n=116)**

679 **Table 1 | Baseline demographic and clinical characteristics of patients in FAS**

| Characteristics                                    | Treatment group (n=99)  | Control Group (n=96)    | Total (n=195)           |
|--|-------------------------|-------------------------|-------------------------|
| Median (IQR) age, years                            | 56.00 (48.50-62.00)     | 56.00 (48.50-62.00)     | 56.00 (48.50- 62.00)    |
| <b>SEX</b>   |                         |                         |                         |
| Male   | 36 (36.4%)              | 37 (38.5%)              | 73 (37.4%)              |
| <b>Disease severity</b>                            |                         |                         |                         |
| Mild and Moderate                                  | 74 (74.7%)              | 89(92.7%)               | 163 (83.6%)             |
| Severe   | 25 (25.3%)              | 7 (7.3%)                | 32 (16.4%)              |
| <b>Coexisting condition</b>                        |                         |                         |                         |
| Hypertension                                       | 63 (63.6%)              | 54 (56.2%)              | 117 (60.0%)             |
| Hyperlipemia                                       | 6 (6.1%)                | 10 (10.4%)              | 16 (8.2%)               |
| Coronary heart disease                             | 7 (7.1%)                | 3 (3.1%)                | 10 (5.1%)               |
| Thyroid disorder                                   | 1 (1.0%)                | 1 (1.0%)                | 2 (1.0%)                |
| Cerebral lacunar infarction                        | 1 (1.0%)                | 3 (3.1%)                | 4 (2.1%)                |
| Diabetes   | 18 (18.2%)              | 9 (9.4%)                | 27 (13.8%)              |
| Rheumatoid disease                                 | 2 (2.0%)                | 1 (1.0%)                | 3 (1.5%)                |
| Chronic bronchitis                                 | 1 (1.0%)                | 1 (1.0%)                | 2 (1.0%)                |
| <b>Symptoms</b>                                    |                         |                         |                         |
| Fever  | 85 (85.9%)              | 90 (93.8%)              | 175 (89.7%)             |
| Cough  | 86 (86.9%)              | 73 (76.0%)              | 159 (81.5%)             |
| Fatigue  | 84 (84.8%)              | 87 (90.6%)              | 171 (87.7%)             |
| Headache   | 14 (14.1%)              | 12 (12.5%)              | 26 (13.3%)              |
| Chest discomfort                                   | 54 (54.5%)              | 59 (61.5%)              | 113 (57.9%)             |
| Sore throat  | 87 (87.9%)              | 87 (90.6%)              | 174 (89.2%)             |
| <b>Laboratory parameters—Median(IQR)/mean (SD)</b> |                         |                         |                         |
| White blood cell count, $\times 10^9/L$            | 5.84 (4.90- 7.29)       | 5.68 (4.78- 6.75)       | 5.77 (4.82- 6.89)       |
| Red blood cell count, $\times 10^{12}/L$           | 4.13 (3.84- 4.44)       | 4.04 (3.67- 4.35)       | 4.06 (3.76- 4.39)       |
| Platelet count, $\times 10^9/L$                    | 229.00 (172.00- 267.50) | 212.00 (184.75- 261.75) | 222.00 (179.50- 265.50) |
| Hemoglobin, g/L                                    | 125.00 (118.00- 135.50) | 122.50 (111.00- 133.50) | 124.00 (116.00- 135.00) |
| Neutrophil count, $\times 10^9/L$                  | 3.66 (2.69- 4.43)       | 3.28 (2.61- 4.19)       | 3.42 (2.67- 4.35)       |
| Lymphocyte count, $\times 10^9/L$                  | 1.73 (1.48- 2.02)       | 1.65 (1.38- 2.07)       | 1.68 (1.42- 2.05)       |
| Monocyte count, $\times 10^9/L$                    | 0.41 (0.35- 0.49)       | 0.38 (0.32- 0.46)       | 0.40 (0.34- 0.48)       |
| Neutrophil percentage, %                           | 59.30 (54.35- 65.55)    | 58.85 (50.53- 64.10)    | 59.10 (52.60- 65.20)    |
| Lymphocyte percentage, %                           | 30.17 (8.41)            | 30.27 (9.54)            | 30.22 (8.96)            |
| Monocyte percentage, %                             | 7.20 (6.10- 7.80)       | 6.80 (5.88- 7.85)       | 7.00 (6.00- 7.80)       |
| Total bilirubin, $\mu\text{mol/L}$                 | 12.20 (10.00- 15.55)    | 11.90 (9.80- 14.88)     | 12.10 (9.85- 15.25)     |

|   |                         |                         |                         |
|---|-------------------------|-------------------------|-------------------------|
| Alanine transaminase, U/L               | 25.00 (19.00- 37.50)    | 27.50 (19.00- 35.00)    | 26.00 (19.00- 35.00)    |
| Glutamic oxalacetic transaminase, U/L   | 25.00 (22.00- 31.00)    | 29.00 (23.00- 34.00)    | 26.00 (22.00- 33.00)    |
| Albumin, g/L                            | 39.40 (37.25- 40.85)    | 39.10 (37.20- 40.50)    | 39.20 (37.20- 40.70)    |
| Urea, mmol/L                            | 4.50 (3.65- 5.23)       | 4.57 (3.60- 5.50)       | 4.54 (3.60- 5.37)       |
| Creatinine, umol/L                      | 62.40 (53.50- 73.90)    | 64.60 (56.50- 73.10)    | 63.00 (54.65- 73.90)    |
| Blood glucose, mmol/L                   | 5.20 (4.80- 6.05)       | 5.10 (4.80- 6.12)       | 5.20 (4.80- 6.10)       |
| Creatine kinase, U/L                    | 63.00 (45.25- 85.75)    | 65.50 (50.00- 95.00)    | 63.50 (48.00- 87.00)    |
| Creatine kinase isoenzyme, U/L          | 10.00 (8.00- 12.00)     | 11.00 (8.00- 12.25)     | 10.00 (8.00- 12.00)     |
| Blood potassium, mmol/L                 | 4.20 (4.00- 4.50)       | 4.30 (4.00- 4.50)       | 4.30 (4.00- 4.50)       |
| Blood sodium, mmol/L                    | 140.00 (139.00- 141.00) | 140.00 (138.00- 142.00) | 140.00 (138.00- 142.00) |
| Blood chlorine, mmol/L                  | 106.00 (104.00- 108.00) | 106.00 (104.00- 107.00) | 106.00 (104.00- 107.00) |
| C-reactive protein, mg/L                | 1.00 (0.50- 2.90)       | 1.00 (0.60- 1.70)       | 1.00 (0.50- 2.38)       |
| Hypersensitive C-reactive protein, mg/L | 1.10 (0.50- 2.00)       | 1.10 (0.50- 2.80)       | 1.10 (0.50- 2.35)       |
| Amyloid protein, mg/L                   | 3.70 (3.70- 6.45)       | 3.70 (3.70- 5.75)       | 3.70 (3.70- 6.15)       |
| Myoglobin, ng/mL                        | 30.60 (24.70- 42.40)    | 32.40 (24.95- 41.85)    | 31.00 (24.80- 41.92)    |
| Hypersensitive troponin, pg/mL          | 1.50 (0.70- 3.40)       | 1.70 (0.70- 3.20)       | 1.70 (0.70- 3.40)       |
| Blood sedimentation, mm/h               | 15.00 (7.00- 23.00)     | 16.00 (11.00- 25.00)    | 16.00 (9.00- 25.00)     |
| Ferritin, ng/mL                         | 196.43 (128.24- 309.99) | 195.99 (114.96- 300.11) | 195.99 (119.33- 309.75) |
| D-dimer, ug/mL                          | 0.38 (0.23- 0.65)       | 0.44 (0.24- 0.84)       | 0.40 (0.24- 0.76)       |
| Interleukin 6, pg/mL                    | 7.02 (5.46- 8.59)       | 6.78 (5.73- 8.43)       | 6.94 (5.54- 8.54)       |
| Procalcitonin , ng/ml                   | 0.05 (0.05- 0.05)       | 0.05 (0.05- 0.05)       | 0.05 (0.05- 0.05)       |
| <b>Chest CT parameters—Median(IQR)</b>  |                         |                         |                         |
| score of ground glass area              | 16.50 (10.25-21.75)     | 17.00 (8.00-27.50)      | 16.75 (9.00-24.12)      |
| Score of consolidation area             | 0.00 (0.00- 0.00)       | 0.00 (0.00-0.00)        | 0.00 (0.00-0.00)        |

680


681 **Table 2 | Summary of adverse events in safety population\***


| Adverse events          | Treatment group (n=100) | Control Group (n=102) | Total (n=202) |
|-------------------------|-------------------------|-----------------------|---------------|
| <b>All adverse even</b> | <b>16</b>               | <b>23</b>             | <b>35</b>     |
| Diarrrhea               | 8 (8%)                  | 7 (6.9%)              | 15 (7.4%)     |
| Abdominal discomfort    | 2 (2%)                  | 7 (2%)                | 5 (2.5%)      |
| Decreased appetite      | 3 (3%)                  | 0 (0)                 | 3 (1.5%)      |
| Anxiety                 | 0 (0)                   | 2 (2.0%)              | 2 (1.0%)      |
| Oral ulcer              | 1 (1%)                  | 1 (1.0%)              | 2 (1.0%)      |
| short breath            | 0 (0)                   | 2 (2.0%)              | 2 (1.0%)      |
| Constipation            | 0 (0)                   | 1 (1.0%)              | 1 (0.5%)      |
| Vomiting                | 1 (1%)                  | 0 (0)                 | 1 (0.5%)      |
| Itchy skin              | 0 (0)                   | 1 (1.0%)              | 1 (0.5%)      |
| Lower extremity edema   | 0 (0)                   | 1 (1.0%)              | 1 (0.5%)      |
| Dry eye                 | 1 (1%)                  | 0 (0)                 | 1 (0.5%)      |
| Limb pain               | 0 (0)                   | 1 (1.0%)              | 1 (0.5%)      |

682 \*Values stand for numbers (percentages of patient happened adverse events)

683


684 Annex 1 Research Period






Number at risk: n (%)





Number at risk: n (%)





Number at risk: n (%)



